Moody's Ratings places Select Medical's ratings on review for downgrade following take private LBO announcement

Moody's Ratings places Select Medical's ratings on review for downgrade following take private LBO announcement

Moody’s Investors Service has placed Select Medical’s credit ratings on review for a potential downgrade following the company’s announcement of a leveraged buyout (LBO) to take the business private. The move reflects concerns about the financial implications of the transaction, including increased leverage and operational risks associated with a private equity-led restructuring. While the LBO aims to streamline operations and improve long-term flexibility, the immediate impact may strain liquidity and amplify exposure to market volatility according to Deutsche Bank analysis.

The decision follows recent scrutiny of Select Medical’s governance practices, including an ongoing investigation into its board for potential fiduciary breaches. These developments add to broader credit risks in the healthcare sector, where regulatory pressures and cost management challenges remain critical factors. Moody’s noted in its recent credit outlook that companies undergoing significant ownership changes face heightened scrutiny, particularly when debt levels rise or operational uncertainties persist.

Analysts at Deutsche Bank previously downgraded Select Medical’s stock, citing risks tied to its acquisition strategy and debt burden. The LBO’s success will depend on the company’s ability to execute cost efficiencies and navigate regulatory and market headwinds. Moody’s review underscores the delicate balance between restructuring opportunities and the financial risks inherent in private equity takeovers, particularly in capital-intensive industries like healthcare. Investors are advised to monitor updates to the company’s credit profile and the broader sector’s response to similar transactions.